'Compounded semaglutide is the same as Ozempic'

A claim-check on the most common GLP-1 compounding claim. Verdict: misleading.

What was said

A claim that spread through telehealth marketing and social media during the GLP-1 boom: compounded semaglutide is the same drug as Ozempic/Wegovy, just cheaper, so sourcing it from a compounder is equivalent S1.

What the record shows

• Compounded drugs are not FDA-approved and do not undergo FDA's premarket review for safety, effectiveness, and quality S1S3.
• FDA has documented concrete, product-level differences and harms: product concentrations vary by compounder, dosing errors have occurred from patients and providers measuring incorrect amounts, and counterfeit products may contain the wrong amount of active ingredient or other ingredients S1S2.
• As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide S2.

Reconciliation

The claim is misleading, not simply false: compounded semaglutide may share the same active ingredient, but "same active ingredient" is not "same product." The absence of FDA review, the concentration variability, the documented dosing errors, and counterfeit risk are exactly the differences the claim erases S1S2.

What would change this verdict

Nothing about the compounded/approved distinction changes on its own. A specific compounded product could only be equated to the approved drug if it were itself FDA-approved — which, by definition, a compounded preparation is not S1S3.